Multiple Sclerosis News

WEST PALM BEACH, Fla. — In two separate cohorts of individuals with multiple sclerosis and memory issues, better sleep was linked to improved verbal memory, according to a poster at ACTRIMS 2024.

WEST PALM BEACH, Fla. — For patients with multiple sclerosis living in underserved areas, increasing access to health care professionals and removing barriers of access to technology are urgent needs, according to a speaker at ACTRIMS 2024.

The FDA has approved a supplemental new drug application for an Acthar Gel injector for the treatment of several chronic and acute inflammatory and autoimmune conditions, according to the manufacturer.

WEST PALM BEACH, Fla. — Application of a machine learning model to databases of patients with multiple sclerosis expanded understanding of disease progression, according to a poster at ACTRIMS 2024.

WEST PALM BEACH, Fla. — In an open-label extension, treatment with ozanimod demonstrated sustained efficacy for disease progression in patients with relapsing multiple sclerosis, per research presented at ACTRIMS 2024.

WEST PALM BEACH, Fla. — Oral administration of vidofludimus calcium reduced fatigue over 14 days compared with placebo and may have a long-term positive effect in multiple sclerosis, according to a poster presented at ACTRIMS 2024.

For individuals with pediatric-onset multiple sclerosis, treatment with commonly known highly effective therapies was associated with reduced relapse risk and optimal outcome within the first 2 years, researchers wrote in JAMA Neurology.

An Indianapolis-area biopharmaceutical company announced it has raised $30 million in Series B financing to advance investigational tyrosine kinase 2 inhibitors for multiple sclerosis as well as dermatologic conditions.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.

The FDA has granted fast track designation for an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate to treat those with refractory progressive multiple sclerosis, according to the manufacturer.